CN112125884A - 制备嘧啶-2,4-二胺二盐酸盐的方法 - Google Patents

制备嘧啶-2,4-二胺二盐酸盐的方法 Download PDF

Info

Publication number
CN112125884A
CN112125884A CN202011050061.0A CN202011050061A CN112125884A CN 112125884 A CN112125884 A CN 112125884A CN 202011050061 A CN202011050061 A CN 202011050061A CN 112125884 A CN112125884 A CN 112125884A
Authority
CN
China
Prior art keywords
phenyl
pyrimidine
isopropoxy
methyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011050061.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·宫
冯丽丽
P·H·卡平斯基
L·M·维科尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112125884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN112125884A publication Critical patent/CN112125884A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202011050061.0A 2010-12-17 2011-12-15 制备嘧啶-2,4-二胺二盐酸盐的方法 Pending CN112125884A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
US61/424,194 2010-12-17
CN201180060435XA CN103282359A (zh) 2010-12-17 2011-12-15 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180060435XA Division CN103282359A (zh) 2010-12-17 2011-12-15 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式

Publications (1)

Publication Number Publication Date
CN112125884A true CN112125884A (zh) 2020-12-25

Family

ID=45464892

Family Applications (7)

Application Number Title Priority Date Filing Date
CN202011050061.0A Pending CN112125884A (zh) 2010-12-17 2011-12-15 制备嘧啶-2,4-二胺二盐酸盐的方法
CN202210792464.5A Pending CN114989139A (zh) 2010-12-17 2011-12-15 制备嘧啶-2,4-二胺二盐酸盐的方法
CN201710063793.5A Pending CN107056751A (zh) 2010-12-17 2011-12-15 一种alk抑制剂的结晶形式
CN201180060435XA Pending CN103282359A (zh) 2010-12-17 2011-12-15 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式
CN201610217386.0A Pending CN106008462A (zh) 2010-12-17 2011-12-15 一种alk抑制剂的结晶形式
CN201710063792.0A Pending CN106831716A (zh) 2010-12-17 2011-12-15 一种alk抑制剂的结晶形式
CN201410457562.9A Pending CN104262324A (zh) 2010-12-17 2011-12-15 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式

Family Applications After (6)

Application Number Title Priority Date Filing Date
CN202210792464.5A Pending CN114989139A (zh) 2010-12-17 2011-12-15 制备嘧啶-2,4-二胺二盐酸盐的方法
CN201710063793.5A Pending CN107056751A (zh) 2010-12-17 2011-12-15 一种alk抑制剂的结晶形式
CN201180060435XA Pending CN103282359A (zh) 2010-12-17 2011-12-15 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式
CN201610217386.0A Pending CN106008462A (zh) 2010-12-17 2011-12-15 一种alk抑制剂的结晶形式
CN201710063792.0A Pending CN106831716A (zh) 2010-12-17 2011-12-15 一种alk抑制剂的结晶形式
CN201410457562.9A Pending CN104262324A (zh) 2010-12-17 2011-12-15 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式

Country Status (36)

Country Link
US (2) US9309229B2 (enExample)
EP (3) EP3453708B8 (enExample)
JP (1) JP5916752B2 (enExample)
KR (4) KR20130130022A (enExample)
CN (7) CN112125884A (enExample)
AR (2) AR084309A1 (enExample)
AU (1) AU2011343775B2 (enExample)
BR (1) BR112013015000A2 (enExample)
CA (1) CA2821102C (enExample)
CL (1) CL2013001723A1 (enExample)
CO (1) CO6801792A2 (enExample)
CY (2) CY1119474T1 (enExample)
DK (2) DK2651918T3 (enExample)
EC (1) ECSP13012770A (enExample)
ES (3) ES2643016T3 (enExample)
GT (1) GT201300153A (enExample)
HR (2) HRP20171477T1 (enExample)
HU (1) HUE041845T2 (enExample)
IL (1) IL226474A (enExample)
LT (2) LT2651918T (enExample)
MA (1) MA34771B1 (enExample)
MX (1) MX338210B (enExample)
MY (2) MY177742A (enExample)
NZ (1) NZ610713A (enExample)
PE (1) PE20140698A1 (enExample)
PH (1) PH12013501254A1 (enExample)
PL (2) PL2651918T3 (enExample)
PT (2) PT2651918T (enExample)
RS (1) RS57771B1 (enExample)
RU (2) RU2746159C2 (enExample)
SG (2) SG10201510082XA (enExample)
SI (2) SI2651918T1 (enExample)
TN (1) TN2013000216A1 (enExample)
TW (2) TWI576343B (enExample)
WO (1) WO2012082972A1 (enExample)
ZA (1) ZA201303599B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651918T (pt) 2010-12-17 2017-10-17 Novartis Ag Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina
KR102156398B1 (ko) 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
LT3209647T (lt) 2014-10-21 2020-09-25 Ariad Pharmaceuticals, Inc. Kristalinės 5-chlor-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il) piperidin-1-il]pirimidin-2,4-diamino formos
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
WO2017158619A1 (en) 2016-03-15 2017-09-21 Natco Pharma Limited A modified process for the preparation of ceritinib and amorphous form of ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
CN113135905B (zh) 2020-01-17 2023-11-21 轩竹生物科技股份有限公司 多环类间变性淋巴瘤激酶抑制剂的晶型
KR20230008047A (ko) * 2020-03-30 2023-01-13 장슈 야홍 메디텍 코퍼레이션 리미티드 니트록솔린 전구약물의 결정 형태, 이를 함유하는 약학 조성물, 및 이의 제조 방법 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016894A1 (en) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2009032694A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
WO2009032668A2 (en) * 2007-08-28 2009-03-12 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009143389A1 (en) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
CN101616895A (zh) * 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2010142766A2 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
US20130261154A1 (en) 2010-12-17 2013-10-03 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
PT2651918T (pt) * 2010-12-17 2017-10-17 Novartis Ag Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina
HUE038046T2 (hu) 2010-12-17 2018-09-28 Reata Pharmaceuticals Inc Antioxidáns gyulladáscsökkentõ pirazolil és pirimidinil triciklusos enonok
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
US9566882B2 (en) 2014-11-21 2017-02-14 Tk Holdings Inc. Airbag module
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
BR112017011538A2 (pt) 2014-12-04 2018-03-13 Bristol-Myers Squibb Company combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016894A1 (en) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CN101616895A (zh) * 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2009032694A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
WO2009032668A2 (en) * 2007-08-28 2009-03-12 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
US20100298295A1 (en) * 2007-08-28 2010-11-25 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009143389A1 (en) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
WO2010142766A2 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors

Also Published As

Publication number Publication date
AR122395A2 (es) 2022-09-07
CN104262324A (zh) 2015-01-07
MX338210B (es) 2016-04-07
EP3453708B8 (en) 2022-03-16
EP3121171B1 (en) 2018-08-15
RU2016136823A3 (enExample) 2020-02-06
MY177742A (en) 2020-09-23
KR102325775B1 (ko) 2021-11-12
RU2013132947A (ru) 2015-01-27
CY1119474T1 (el) 2018-04-04
CO6801792A2 (es) 2013-11-29
GT201300153A (es) 2014-06-09
US20130274279A1 (en) 2013-10-17
CN106831716A (zh) 2017-06-13
SG190856A1 (en) 2013-07-31
RU2599785C2 (ru) 2016-10-20
KR20180032680A (ko) 2018-03-30
RU2599785C3 (ru) 2019-04-24
PH12013501254A1 (en) 2016-07-29
SI3121171T1 (sl) 2018-11-30
TW201307299A (zh) 2013-02-16
ECSP13012770A (es) 2013-10-31
CN107056751A (zh) 2017-08-18
NZ610713A (en) 2014-10-31
CL2013001723A1 (es) 2013-12-27
US20160175305A1 (en) 2016-06-23
KR20190022903A (ko) 2019-03-06
ES2905973T3 (es) 2022-04-12
ZA201303599B (en) 2014-02-26
IL226474A (en) 2016-03-31
EP3453708A1 (en) 2019-03-13
DK2651918T3 (en) 2017-10-23
CY1121017T1 (el) 2019-12-11
CA2821102C (en) 2019-06-11
PT2651918T (pt) 2017-10-17
PE20140698A1 (es) 2014-06-11
TWI576344B (zh) 2017-04-01
DK3121171T3 (en) 2018-12-10
PL2651918T3 (pl) 2017-12-29
AU2011343775B2 (en) 2015-12-03
AR084309A1 (es) 2013-05-08
EP2651918B1 (en) 2017-07-12
AU2011343775A1 (en) 2013-07-18
CN106008462A (zh) 2016-10-12
ES2696526T3 (es) 2019-01-16
JP5916752B2 (ja) 2016-05-11
ES2643016T3 (es) 2017-11-21
US9309229B2 (en) 2016-04-12
EP2651918A1 (en) 2013-10-23
TW201629021A (zh) 2016-08-16
EP3121171A1 (en) 2017-01-25
HRP20171477T1 (hr) 2017-11-17
MY164810A (en) 2018-01-30
CN103282359A (zh) 2013-09-04
LT2651918T (lt) 2017-10-10
SI2651918T1 (sl) 2017-10-30
RU2746159C2 (ru) 2021-04-08
MX2013006952A (es) 2013-07-15
JP2013545812A (ja) 2013-12-26
CA2821102A1 (en) 2012-06-21
TWI576343B (zh) 2017-04-01
EP3453708B1 (en) 2021-10-27
WO2012082972A1 (en) 2012-06-21
KR20130130022A (ko) 2013-11-29
TN2013000216A1 (en) 2014-11-10
PL3121171T3 (pl) 2019-01-31
KR20200039021A (ko) 2020-04-14
SG10201510082XA (en) 2016-01-28
MA34771B1 (fr) 2013-12-03
HUE041845T2 (hu) 2019-05-28
HRP20181737T1 (hr) 2018-12-28
CN114989139A (zh) 2022-09-02
RU2016136823A (ru) 2018-12-11
RS57771B1 (sr) 2018-12-31
BR112013015000A2 (pt) 2016-08-09
PT3121171T (pt) 2018-11-27
LT3121171T (lt) 2018-11-12
IL226474A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US9309229B2 (en) Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
US10202364B2 (en) Forms and compositions of an ERK inhibitor
HK40003121A (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
HK40003121B (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
HK1186726B (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1186726A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1230180A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1230180B (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination